OncoMatch/Clinical Trials/NCT06387121
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Is NCT06387121 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for precursor cell lymphoblastic leukemia-lymphoma.
Treatment: Vincristine · Cyclophosphamide · Dexamethasone · Venetoclax · Inotuzumab ozogamicin · Blinatumomab · 6-mercaptopurine · Methotrexate · Cytarabine · Prednisone — In the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL) among adult patients, therapeutic outcomes remain suboptimal despite advances in chemotherapy and immunotherapy. A subset of adults with Ph- B-ALL have comorbidities or physiological limitations that preclude the safe administration of intensive regimens. In recent years, tumor immunotherapy has demonstrated promising safety and efficacy profiles in refractory or relapsed Ph- B-ALL across a wide spectrum of adult ages. These findings suggest that broader application of immunotherapy may represent a critical strategy to improve survival in this population. In this study, we propose a regimen that combines immuno-targeted agents with low-intensity chemotherapy for newly diagnosed adult patients with Ph- B-ALL. Our primary objective is to increase the rate of measurable residual disease (MRD)-negative complete remission (CR) following induction therapy, reduce the risk of relapse, and ultimately enhance overall survival.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD22 positive (positive)
CD22 positive tumor cells
Required: BCR wild-type
Ph-negative
Required: ABL1 wild-type
Ph-negative
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06387121 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD22?
Yes, CD22 positive is a required biomarker for enrollment.
Does this trial require BCR?
Yes, BCR wild-type is a required biomarker for enrollment.
Does this trial require ABL1?
Yes, ABL1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify